Tumour Kinetics in Multiple Myeloma Before, During, and After Treatment

References

• Blade J., Samson D., Reece D., Apperley J., Bjorkstrand B., Gahrton G., Gertz M., Girait S., Jagannath S., Vesole D. Criteria for evaluating disease response and progression in multiple myeloma patients treated by high dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123
   PubMed Web of Science ®Google Scholar
• Witzig T. E., Gertz M. A., Lust J. A., Kyle R. A., O'Fallon W. M., Greípp P. R. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]. Blood 1996; 88: 1780–1787
   PubMed Web of Science ®Google Scholar
• Omede P., Boccadoro M., Gallone G., Frieri R., Battaglio S., Redoglia V., Pileri A. Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. Blood 1990; 76: 1375–1379
   PubMed Web of Science ®Google Scholar
• Billadeau D., Van Ness B., Kimlinger T., Kyle R. A., Therneau T. M., Greipp P. R., Witzig T. E. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 1996; 88: 289–296
   PubMed Web of Science ®Google Scholar
• Pilarski L. M., Belch A. R. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Blood 1994; 83: 724–736
   PubMed Web of Science ®Google Scholar
• To L. B., Roberts M. M., Haylock D. N., Dyson P. G., Branford A. L., Thorp D., Ho J. Q., Dart G. W., Horvath N., Davy M. L. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277–284
   PubMed Web of Science ®Google Scholar
• Dimopoulos M. A., Alexanian R., Przepiorka D., Hester J., Andersson B., Girait S., Mehra R., van Besien K., Delasalle K. B., Reading C. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82: 2324–2328
   PubMed Web of Science ®Google Scholar
• Henry J. M., Sykes P. J., Brisco M. J., To L. B., Juttner C. A., Morley A. A. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br J Haematol 1996; 92: 614–619
   PubMed Web of Science ®Google Scholar
• Vescio R. A., Han E. J., Schiller G. J., Lee J. C., Wu C. H., Cao J., Shin J., Kim A., Lichtenstein A. K., Berenson J. R. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant 1996; 18: 103–110
   PubMed Web of Science ®Google Scholar
• Bird J. M., Bloxham D., Samson D., Marcus R. E., Russell N. H., Kelsey S. M., Newland A. C., Apperley J. F. Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol 1994; 88: 110–116
   PubMed Web of Science ®Google Scholar
• Craig J. I., Langlands K., Parker A. C., Anthony R. S. Molecular detection of tumor contamination in peripheral blood stem cell harvests. Exp Hematol 1994; 22: 898–902
   PubMed Web of Science ®Google Scholar
• Mariette X., Fermand J. P., Brouet J. C. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy. Bone Marrow Transplant 1994; 14: 47–50
   PubMed Web of Science ®Google Scholar
• Corradini P., Voena C., Astolfi M., Ladetto M., Tarella C., Boccadoro M., Pileri A. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995; 85: 1596–1602
   PubMed Web of Science ®Google Scholar
• Witzig T. E., Gertz M. A., Lust J. A., Kyle R. A., Greipp P. R. Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: when is the optimal time for stem cell harvest?. Leuk Lymphoma 1995; 19: 417–422
   PubMed Web of Science ®Google Scholar
• Brenner M. K., Rill D. R., Moen R. C., Krance R. A., Mirro J., Jr, Anderson W. F., Ihle J. N. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–86
   PubMed Web of Science ®Google Scholar
• Deisseroth A. B., Zu Z., Claxton D., Hanania E. G., Fu S., Ellerson D., Goldberg L., Thomas M., Janicek K., Anderson W. F. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068–3076
   PubMed Web of Science ®Google Scholar
• Gertz M. A., Witzig T. E., Pineda A. A., Greipp P. R., Kyle R. A., Litzow M. R. Monoclonal plasma cells in the blood stem cell harvests from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant 1997; 19: 337–342
   PubMed Web of Science ®Google Scholar
• Voena C., Ladetto M., Astolfi M., Provan D., Gribben J. G., Boccadoro M., Pileri A., Corradini P. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumours. Leukemia 1997; 11: 1793–1798
   PubMed Web of Science ®Google Scholar
• Spencer A., Seldon M., McArthy S. F., Deveridge N., Marlton P., Enno A., Cobcroft R., Gill D. S. A phase 11 study of CID therapy and early PBSCT in patients with de novo multiple myeloma. Br J Haematol 1998; 102: 352a
   Web of Science ®Google Scholar
• Miller S. A., Dykes D. D., Polesky H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215
   PubMed Web of Science ®Google Scholar
• Spencer A., Vulliamy T., Kaeda J., Goldman J. M., Melo J. V. Clonal instability preceeding lymphoid blastic transformation of chronic myeloid leukemia. Leukemia 1997; 11: 195–201
   PubMed Web of Science ®Google Scholar
• Aubin J., Davi F., Nguyen-Salomon F., Leboeuf D., Debert C., Taher M., Valensi F., Canioini D., Brousse N., Varet B., Flandrin G., Macintyre E. A. Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia 1995; 9: 471–479
   PubMed Web of Science ®Google Scholar
• Deane M., Norton J. D. Immunoglobulin gene “fingerprinting”: an approach to analysis of B lymphoid clonality in lymphoproliferative disorders. Br J Haematol 1991; 77: 274–281
   PubMed Web of Science ®Google Scholar
• Tomlinson I. M., Walter G., Marks J. D., Llewelyn M. B., Winter G. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol 1992; 227: 776–798
   PubMed Web of Science ®Google Scholar
• Vulliamy T., Rovira A., Yusoff N., Colomer D., Luzzatto L., Vives-Corrons J. L. Independent origin of single and double mutations in the human glucose 6-phosphate dehydrogenase gene. Hum Mutat 1996; 8: 311–318
   PubMed Web of Science ®Google Scholar
• Rettig M. B., Vescio R. A., Cao J., Wu C. H., Lee J. C., Han E., DerDanielian M., Newman R., Hong C., Lichten-stein A. K., Berenson J. R. VH gene usage in multiple myeloma: complete absence of the VH4.21 (VH4–34) gene. Blood 1996; 87: 2846–2852
   PubMed Web of Science ®Google Scholar
• Owen R. G., Johnson R. J., Rawstron A. C., Evans P. A., Jack A., Smith G. M., Child J. A., Morgan G. J. Assessment of IgH PCR strategies in multiple myeloma. J Clin Pathol 1996; 49: 672–675
   PubMed Web of Science ®Google Scholar
• Brisco M. J., Tan L. W., Orsborn A. M., Morley A. A. Development of a highly sensitive assay, based on the polymerase chain reaction, for rare B-lymphocyte clones in a polyclonal population. Br J Haematol 1990; 75: 163–167
   PubMed Web of Science ®Google Scholar
• Billadeau D., Blackstadt M., Greipp P., Kyle R. A., Oken M. M., Kay N., Van Ness B. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease. Blood 1991; 78: 3021–3029
   PubMed Web of Science ®Google Scholar
• Gazitt Y., Tian E., Barlogie B., Reading C. L., Vesole D. H., Jagannath S., Schnell J., Hoffman R., Tricot G. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1996; 87: 805–811
   PubMed Web of Science ®Google Scholar
• Cremer F. W., Kiel K., Sucker C., Wacker J., Atzberger A., Haas R., Goldschmidt H., Moos M. A rationale for positive selection of peripheral blood stem cells in multiple myeloma: highly purified CD34+ cell fractions of leukapheresis products do not contain malignant cells. Leukemia 1997; 11(Suppl 5)S41–46
   PubMedGoogle Scholar
• Gerard C. J., Olsson K., Ramanathan R., Reading C., Hanania E. G. Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards. Cancer Res 1998; 58: 3957–3964
   PubMed Web of Science ®Google Scholar
• Billadeau D., Quam L., Thomas W., Kay N., Greipp P., Kyle R., Oken M. M., Van Ness B. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992; 80: 1818–1824
   PubMed Web of Science ®Google Scholar
• Corradini P., Voena C., Omede P., Astolfi M., Boccadoro M., Dalla-Favera R., Pileri A. Detection of circulating tumor cells in multiple myeloma by a PCR-based method. Leukemia 1993; 7: 1879–1882
   PubMed Web of Science ®Google Scholar
• Bergsagel P. L., Smith A. M., Szczepek A., Mant M. J., Belch A. R., Pilarski L. M. In multiple myeloma, clonotypic B lymphocytes are detectable among CD 19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain [published erratum appears in Blood 1995 Jun 1; 85(11):3365]. Blood 1995; 85: 436–447
   PubMed Web of Science ®Google Scholar
• Szczepek A. J., Seeberger K., Wizniak J., Mant M. J., Belch A. R., Pilarski L. M. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 1998; 92: 2844–2855
   PubMed Web of Science ®Google Scholar
• Billadeau D., Prosper F., Verfaillie C., Weisdorf D., Van Ness B. Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumour involvement. Leukemia 1997; 11: 1565–1570
   PubMed Web of Science ®Google Scholar
• Kiel K., Cremer F. W., Ehrbrecht E., Wallmeier M., Hegenbart U., Goldschmidt H., Moos M. First and second apheresis in patients with multiple myeloma: no differences in tumour load and hematopoietic stem cell yeild. Bone Marrow Transplant 1998; 21: 1109–1115
   PubMed Web of Science ®Google Scholar
• Lemoli R. M., Cavo M., Fortune A. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma. J Hematother 1996; 5: 339–349
   PubMedGoogle Scholar
• Gazitt Y., Reading C. C., Hoffman R., Wickrema A., Vesole D. H., Jagannath S., Condino J., Lee B., Barlogie B., Tricot G. Purified CD34+ Lin-Thy+ stem cells do not contain clonal myeloma cells. Blood 1995; 86: 381–389
   PubMed Web of Science ®Google Scholar
• Omede P., Tarella C., Palumbo A., Argentino C., Caracciolo D., Corradini P., Dominietto A., Giaretta F., Ravaglia R., Triolo R., Triolo S., Pileri A., Boccadoro M. Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses. Br J Haematol 1997; 99: 685–691
   PubMed Web of Science ®Google Scholar
• Brugger W., Bross K. J., Glatt M., Weber F., Mertelsmann R., Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors [see comments]. Blood 1994; 83: 636–640
   PubMed Web of Science ®Google Scholar
• Anderson K. C., Jones R. M., Morimoto C., Leavitt P., Barut B. A. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989; 73: 1915–1924
   PubMed Web of Science ®Google Scholar
• Villunger A., Egle A., Kos M., Egle D., Tinhofer I., Henn T., Uberall F., Maly K., Greil R. Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity. Br J Haematol 1998; 102: 1069–1080
   PubMed Web of Science ®Google Scholar